EGFR and non-small cell lung carcinoma: Promising results have been obtained with EGFR inhibitors, which after several randomized phase 3 trials have been approved as first-line treatment in advanced NSCLC patients positive for EGFR mutations, showing higher progression-free survival and lower toxicity when compared to standard chemotherapy [181].